Jennifer Couzin. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » AdolescentAdultAutoantibodies/immunologyChildClinical Trials as TopicDiabetes Mellitus, Type 1/drug therapyDiabetes Mellitus, Type 1/geneticsDiabetes Mellitus, Type 1/immunologyDiabetes Mellitus, Type 1/prevention & controlDisease ProgressionHumansImmunosuppressive Agents/adverse effectsImmunosuppressive Agents/therapeutic useInfantInfant FoodInsulin/administration & dosageInsulin/therapeutic useIslets of Langerhans/immunologyMuromonab-CD3/adverse effectsMuromonab-CD3/therapeutic useNational Institutes of Health (U.S.)Niacinamide/administration & dosageNiacinamide/therapeutic usePeptides/therapeutic useRisk FactorsT-Lymphocytes/immunologyTwin Studies as TopicUnited States
Substances: See more » AutoantibodiesImmunosuppressive AgentsInsulinMuromonab-CD3Peptidesmonoclonal antibody huOKT3(Ala-Ala)Niacinamide
Year: 2003 PMID: 12817117 DOI: 10.1126/science.300.5627.1862
Source DB: PubMed Journal: Science ISSN: 0036-8075 Impact factor: 47.728